Literature DB >> 24576181

MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1.

Qing-Fu Xu1, Ya-Wen Pan, Li-Chao Li, Zheng Zhou, Qi-Lin Huang, Jesse Chung-Sean Pang, Xiao-Peng Zhu, Yong Ren, Hui Yang, Hiroko Ohgaki, Sheng-Qing Lv.   

Abstract

Medulloblastoma is the most frequent malignant central nervous system tumor in children. MicroRNAs (miRs) are small, non-coding RNAs that target protein-coding and non-coding RNAs, and play roles in a variety of cellular processes through regulation of multiple targets. In the present study, we analyzed miR-22 expression and its effect in cell proliferation and apoptosis in medulloblastomas. Quantitative reverse transcription PCR (RT-PCR) revealed significantly lower expression of miR-22 in 19 out of 27 (70%) medulloblastomas, D341, DAOY, ONS-76 medulloblastoma cell lines, compared with normal cerebellum. Forced expression of miR-22 by lentiviral vector transfection reduced cell proliferation and induced apoptosis, while knockdown of miR-22 increased proliferative activity in DAOY and ONS-76 cells. DAOY cells with miR-22 overexpression in nude mice yielded tumors smaller than those originated from control DAOY cells. Microarray analysis in DAOY cells with forced miR-22 expression showed significant changes in expression profiles, PAPST1 being the most significantly (10 folds) downregulated gene. Quantitative RT-PCR revealed PAPST1 mRNA upregulation in 18 out of 27 (67%) medulloblastomas. In addition, a luciferase reporter assay in ONS-76 and DAOY cells suggested that miR-22 directly targets the PAPST1 gene, and lentivirus-mediated knockdown of PAPST1 suppressed proliferation of DAOY and ONS-76 medulloblastoma cells. These results suggest that frequently downregulated miR-22 expression is associated with cell proliferation in medulloblastomas, and this may be at least in part via PAPST1, which is a novel target of miR-22.
© 2014 International Society of Neuropathology.

Entities:  

Keywords:  PAPST1; apoptosis; cell proliferation; medulloblastoma; miR-22

Mesh:

Substances:

Year:  2014        PMID: 24576181     DOI: 10.1111/bpa.12136

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  15 in total

1.  TROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy.

Authors:  Guihong Wang; Zhenhua Zhang; Yongqiang Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 2.  MicroRNA-22: a Novel and Potent Biological Therapeutics in Neurological Disorders.

Authors:  Seyed Hamidreza Rastegar-Moghaddam; Alireza Ebrahimzadeh-Bideskan; Sara Shahba; Amir Mohammad Malvandi; Abbas Mohammadipour
Journal:  Mol Neurobiol       Date:  2022-02-14       Impact factor: 5.590

Review 3.  Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.

Authors:  Alti Dayakar; Kumar D Shanmukha; Suresh K Kalangi
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.742

4.  ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.

Authors:  Qingfu Xu; Chengchen Hu; Yan Zhu; Kimberly Wang; Bachuchu Lal; Lichao Li; Junhai Tang; Shuang Wei; Guohao Huang; Shuli Xia; Shengqing Lv; John Laterra; Yugang Jiang; Yunqing Li
Journal:  Cancer Lett       Date:  2020-01-16       Impact factor: 8.679

Review 5.  Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.

Authors:  Austin W T Chiang; Hratch M Baghdassarian; Benjamin P Kellman; Bokan Bao; James T Sorrentino; Chenguang Liang; Chih-Chung Kuo; Helen O Masson; Nathan E Lewis
Journal:  J Biomed Sci       Date:  2021-06-22       Impact factor: 8.410

Review 6.  MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown.

Authors:  Maria Braoudaki; George I Lambrou
Journal:  J Hematol Oncol       Date:  2015-02-06       Impact factor: 17.388

7.  The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote T(H)17 cell-dependent emphysema.

Authors:  Wen Lu; Ran You; Xiaoyi Yuan; Tianshu Yang; Errol L G Samuel; Daniela C Marcano; William K A Sikkema; James M Tour; Antony Rodriguez; Farrah Kheradmand; David B Corry
Journal:  Nat Immunol       Date:  2015-10-05       Impact factor: 25.606

8.  Dysregulated function of normal human epidermal keratinocytes in the absence of filaggrin.

Authors:  Ningning Dang; Xiaoli Ma; Xianguang Meng; Liguo An; Shuguang Pang
Journal:  Mol Med Rep       Date:  2016-07-22       Impact factor: 2.952

Review 9.  Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review).

Authors:  Jingyu Wang; Yuan Li; Meiman Ding; Honghe Zhang; Xiaoming Xu; Jinlong Tang
Journal:  Int J Oncol       Date:  2016-12-19       Impact factor: 5.650

10.  Response of MiRNA-22-3p and MiRNA-149-5p to Folate Deficiency and the Differential Regulation of MTHFR Expression in Normal and Cancerous Human Hepatocytes.

Authors:  Chao Li; Juan Ni; Yao-Xian Liu; Han Wang; Zi-Qing Liang; Xu Wang
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.